https://epalrestatinhibitor.co....m/restriction-of-cd4
In patients who displayed poor adherence, sham-treated subjects exhibited an increasing trend in adherence and a significant decrease in ASBP, in contrast to those in the uRDN group, who demonstrated no change. Likewise, shifts in adherence, and the resultant reduction in ASBP in sham subjects with poor adherence, may be the reason for the lack of between-group distinction seen in the REQUIRE study. Ensuring medication adherence through monitoring is crucial for future interv
Like
Comment
Share
